智雲健康(09955.HK)與華潤三九子公司訂立戰略合作協議
格隆匯3月6日丨智雲健康(09955.HK)發佈公吿,公司於2024年3月5日與華潤三九(000999.SZ)的全資子公司昆明華潤聖火藥業有限公司(“華潤聖火”)訂立不具法律約束力的戰略合作協議。
根據戰略合作協議,集團將成為華潤聖火理洫王®血塞通軟膠囊產品於該產品核心銷售省份醫院渠道的總代理,期限為三年。在合作期間,公司將充分依託其數字化能力優勢和完善的醫院渠道資源,進一步提升理洫王®血塞通軟膠囊產品的患者可及性與推廣效率,提升產品的品牌力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.